New cancer indications advance while autism evidence needs separate scrutiny
FDA added specific cancer treatment indications in early October, making the earlier claim of no new approvals outdated. The advances concern defined patient groups and measured clinical endpoints. Autism service funding and vaccine-safety research require their own evidence and should remain clearly separated.
Article updated Oct 11, 2026, 1:36 PM Pacific
Colon cancer after surgery
The October 8 approval adds atezolizumab with fluoropyrimidine and oxaliplatin for Stage III mismatch-repair-deficient colon cancer. The intravenous formulation covers ages two and older; the subcutaneous combination requires age twelve or older and weight of at least 40 kilograms.
The endpoint behind the decision
The colon-cancer trial measured disease-free survival after surgery. A favorable hazard ratio is not the same as an absolute cure rate or a proven gain in overall survival.
Breast-cancer maintenance
On October 7, FDA approved tucatinib with trastuzumab and pertuzumab after induction treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer. The trial improved progression-free survival; overall-survival data were immature.
Another defined blood-cancer population
The October 2 pirtobrutinib approval covers previously untreated adults with chronic lymphocytic leukemia or small lymphocytic lymphoma and no known 17p deletion. Its overall-survival evidence also remained immature.
Autism services and causation
The September dental-care awards support access for children with neurodevelopmental disorders. They do not identify autism’s causes. WHO’s December 2025 expert review found that high-quality evidence does not support a causal vaccine–autism relationship.
The next useful evidence
For cancer, follow mature survival, toxicity and access for each approved population. For autism, distinguish service outcomes, genetic and environmental research, and well-designed causal studies rather than treating unrelated announcements as one finding.
What to watch next
Mature survival, specific treatment toxicity, real-world access, dental-service outcomes and rigorous autism research.
Material unknowns
- Genetic findings, prenatal or perinatal exposures, environmental associations, diagnostic and surveillance changes and proposed mechanisms remain distinct evidence categories. No robust replicated evidence establishes a single autism cause, and high-quality evidence does not support a causal vaccine–autism relationship; legitimate vaccine-safety surveillance remains necessary. The existing imlunestrant-plus-abemaciclib approval is for a defined ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast-cancer population; overall survival was immature and it is not a cure.
U.S. strategic assessment
High interestObjectives
- Protect U.S. security, economic resilience, and citizens using measurable, lawful action.
Strategy
- Use primary records, allied coordination, market evidence, and independent verification to distinguish action from rhetoric.
Risks
- Genetic findings, prenatal or perinatal exposures, environmental associations, diagnostic and surveillance changes and proposed mechanisms remain distinct evidence categories. No robust replicated evidence establishes a single autism cause, and high-quality evidence does not support a causal vaccine–autism relationship; legitimate vaccine-safety surveillance remains necessary. The existing imlunestrant-plus-abemaciclib approval is for a defined ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast-cancer population; overall survival was immature and it is not a cure.
Sources
01Original official record; actions, dates and measured results are kept separate.
Original official record; distinguishes actions from claimed outcomes.
Population, trial stage and company-reported survival signal.
Earlier hazard ratio, confidence interval, comparator and follow-up.
Trial design, endpoints and regulatory registry.
Dated evidence supporting the article; publication and observation periods remain distinct.
Dated evidence supporting the article; publication and observation periods remain distinct.
Dated evidence supporting the article; publication and observation periods remain distinct.
Dated evidence supporting the article; publication and observation periods remain distinct.